not-yet-known not-yet-known not-yet-known unknown Introduction and Objectives: ImmunoCAP Phadiatop (Thermo Fisher Scientific) is an in vitro assay detecting IgE antibodies against a balanced mixture of common inhalant allergens, serving as a first level screening tool for sensitization in patients with suspected respiratory allergies guiding subsequent management. This study aimed to evaluate test results, the impact on clinical decision-making, and its role in managing allergic condition. Materials and Methods: A real-world retrospective observational study was conducted in a tertiary hospital allergy department (June 2021–June 2023). Data were collected using the Modulab Laboratory Information System (Werfen, Spain) and stored in a dissociated database. The Ethics Committee of Salamanca approved the study protocol. Phadiatop values above 0.35 PAU/l were considered positive. In case of repeated samples, the first was selected. Variables analyzed included test results, patient demographics, requesting departments, and allergy referrals. Results: The study included 596 patients (median age 46, 64.1% female). Of these, 12.6% were under 18 years old. Most patients (95.8%) were referred from primary care, with 83.1% originating from urban areas. Positive results occurred in 37.9% (median IgE 7.81 PAU/l). Most positive patients resided in urban areas (82.3%), were aged < 18 years (p=0.001), and were male (p<0.001). Patients aged >59 (26.3%) presented mainly negative results (82.2%). Of the positive cases, 31.4% were referred to an allergist, with higher Phadiatop values increasing referrals (p=0.001). Conclusions: Phadiatop was mainly utilized in primary care. One-third of patients tested positive; of those, only one-third were referred to allergists, with higher Phadiatop values increasing referral rates. Positivity was higher in males and younger people.